Core Insights - Eli Lilly and Company is set to present new data from its breast oncology portfolio at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025, highlighting advancements in treatments for ER+, HER2– metastatic breast cancer [1][2][5] Group 1: Inluriyo (imlunestrant) - Updated results from the Phase 3 EMBER-3 trial will be shared, focusing on Inluriyo alone and in combination with Verzenio in patients with ER+, HER2– advanced or metastatic breast cancer, including overall survival and progression-free survival analyses [2][5] - An exploratory analysis of early changes in circulating tumor DNA (ctDNA) and its correlation to clinical outcomes will also be presented [2] Group 2: Verzenio (abemaciclib) - A subgroup analysis from the Phase 3 monarchE trial will evaluate the efficacy of adjuvant abemaciclib plus endocrine therapy based on nodal status in high-risk early breast cancer patients [3][5] - Recent results indicated that this combination therapy prolonged overall survival and improved invasive disease-free survival and distant relapse-free survival [3] Group 3: LY4064809 (STX-478) - Findings from the ongoing Phase 1/2 PIKALO-1 study of LY4064809, a pan-mutant-selective PI3K inhibitor, will be presented, including safety and efficacy data across various patient subgroups [4][5] - LY4064809 is planned to advance into the Phase 3 PIKALO-2 study, with ongoing dose optimization [4] Group 4: Company Commitment - Eli Lilly emphasizes its commitment to addressing key biological targets in HR+ breast cancer, including CDK4/6, estrogen receptor, and PI3K, reflecting the momentum of its breast oncology portfolio [5]